TY - JOUR
T1 - Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival
T2 - FAST-MI (French registry of acute coronary syndrome)
AU - Puymirat, Etienne
AU - Taldir, Guillaume
AU - Aissaoui, Nadia
AU - Lemesle, Gilles
AU - Lorgis, Luc
AU - Cuisset, Thomas
AU - Bourlard, Pierre
AU - Maillier, Bruno
AU - Ducrocq, Gregory
AU - Ferrieres, Jean
AU - Simon, Tabassome
AU - Danchin, Nicolas
N1 - Funding Information:
FAST-MI is a registry from the French Society of Cardiology that is supported by unrestricted grants from Pfizer and Servier and an additional grant from the Caisse Nationale d'Assurance-Maladie-Travailleurs Salariés . Dr. Ducrocq has a relationship with Medtronic, Inc., AstraZeneca Pharmaceuticals, and Eli Lilly. Dr. Simon has received research grants from Pfizer and Servier for the FAST-MI registry; served as a board member for Bayer; and has given lectures to Sanofi and Lilly. Dr. Danchin has received research grants from AstraZeneca , Daiichi-Sankyo , Eli Lilly , GlaxoSmithKline , MSD , Novartis , Sanofi-Aventis , Servier , and The Medicines Company ; and has served on advisory panels or received lecture fees from AstraZeneca, Boeheringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Menarini, Merck-Serono, Novo-Nordisk, Roche, Servier, and Sanofi-Aventis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/9
Y1 - 2012/9
N2 - Objectives: This study sought to assess the impact of invasive strategy (IS) versus a conservative strategy (CS) on in-hospital complications and 3-year outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) from the FAST-MI (French Registry of Acute Coronary Syndrome). Background: Results from randomized trials comparing IS and CS in patients with NSTEMI are conflicting. Methods: Of the 3,670 patients in FAST-MI, which included patients with acute myocardial infarction (within 48 h) over a 1-month period in France at the end of 2005, 1,645 presented with NSTEMI. Results: Of the 1,645 patients analyzed, 80% had an IS. Patients in the IS group were younger (67 ± 12 years vs. 80 ± 11 years), less often women (29% vs. 51%), and had a lower GRACE (Global Registry of Acute Coronary Events) risk score (137 ± 36 vs. 178 ± 34) than patients treated with CS. In-hospital mortality and blood transfusions were significantly more frequent in patients with CS versus IS (13.1% vs. 2.0%, 9.1% vs. 4.6%). Use of IS was associated with a significant reduction in 3-year mortality and cardiovascular death (17% vs. 60%, adjusted hazard ratio [HR]: 0.44, 95% confidence interval [CI]: 0.35 to 0.55 and 8% vs. 36%, adjusted HR: 0.37, 95% CI: 0.27 to 0.50). After propensity score matching (181 patients per group), 3-year survival was significantly higher in patients treated with IS. Conclusions: In a real-world setting of patients admitted with NSTEMI, the use of IS during the initial hospital stay is an independent predictor of improved 3-year survival, regardless of age. (French Registry of Acute Coronary Syndrome [FAST-MI]; NCT00673036)
AB - Objectives: This study sought to assess the impact of invasive strategy (IS) versus a conservative strategy (CS) on in-hospital complications and 3-year outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) from the FAST-MI (French Registry of Acute Coronary Syndrome). Background: Results from randomized trials comparing IS and CS in patients with NSTEMI are conflicting. Methods: Of the 3,670 patients in FAST-MI, which included patients with acute myocardial infarction (within 48 h) over a 1-month period in France at the end of 2005, 1,645 presented with NSTEMI. Results: Of the 1,645 patients analyzed, 80% had an IS. Patients in the IS group were younger (67 ± 12 years vs. 80 ± 11 years), less often women (29% vs. 51%), and had a lower GRACE (Global Registry of Acute Coronary Events) risk score (137 ± 36 vs. 178 ± 34) than patients treated with CS. In-hospital mortality and blood transfusions were significantly more frequent in patients with CS versus IS (13.1% vs. 2.0%, 9.1% vs. 4.6%). Use of IS was associated with a significant reduction in 3-year mortality and cardiovascular death (17% vs. 60%, adjusted hazard ratio [HR]: 0.44, 95% confidence interval [CI]: 0.35 to 0.55 and 8% vs. 36%, adjusted HR: 0.37, 95% CI: 0.27 to 0.50). After propensity score matching (181 patients per group), 3-year survival was significantly higher in patients treated with IS. Conclusions: In a real-world setting of patients admitted with NSTEMI, the use of IS during the initial hospital stay is an independent predictor of improved 3-year survival, regardless of age. (French Registry of Acute Coronary Syndrome [FAST-MI]; NCT00673036)
UR - http://www.scopus.com/inward/record.url?scp=84866345591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866345591&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2012.05.008
DO - 10.1016/j.jcin.2012.05.008
M3 - Article
C2 - 22995875
AN - SCOPUS:84866345591
VL - 5
SP - 893
EP - 902
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
SN - 1936-8798
IS - 9
ER -